EZH2 inhibition alone or in combination with histone deacetylases (HDAC) inhibitors has been suggested for both tumor types, but antagonistic effects of this drug combination on in vitro rhabdoid tumor cell proliferation have also been demonstrated [10–12]. Here, EZH2 is linked to rhabdoid tumor.